tbuckley/cabot-search huggingface dataset:
Influence of eribulin on proliferation, migration and invasion properties of leiomyosarcoma cell line models
Authors: M. Mendiola, V. Heredia-Soto, J. Escudero, R. Crespo, P. Ruiz, A Gallego Martínez, V. Martínez-Marin, J.J. Pozo, A. Berjón, E. Ortiz-Cruz, D. Bernabeu, A. Redondo
Journal: Annals of Oncology (2019)
IKS01, a next generation antibody drug conjugate (ADC) designed to be efficacious in tumors with low and moderate levels of folate receptor expression
Authors: J. Thirlway, A. Lodge, A. Pelava, D.J. Williamson, D. Carta, M Al Nakeeb, J. Mysliwy, P.J.M. Jackson, D.E. Thurston, R.J. Lutz
Journal: Annals of Oncology (2019)
Buparlisib (BKM120) in refractory head and neck squamous cell carcinoma harbouring or not a PI3KCA mutation: A phase II multicenter trial
Authors: J. Fayette, L. Digue, C. Ségura-Ferlay, I. Treilleux, Q. Wang, G. Lefebvre, A. Daste, C. Even, S. Couchon Thaunat, A. Guyennon, F. Peyrade, D. Cupissol, B. You, C. Le Tourneau, L. Jaouen, E. Grinand, S. Tabone-Eglinger, G. Garin, D. Perol
Journal: Annals of Oncology (2019)
A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft tissue sarcomas who are not candidates for chemotherapy
Authors: A. Hirbe, J. Luo, M. Seetharam, J. Toeniskoetter, T. Kershner, M. Agulnik, M. Varun, M. Milhem, A. Parkes, S. Robinson, S. Okuno, S. Attia, B.A. Van Tine
Journal: Annals of Oncology (2019)
Outcomes of Autologous Stem Cell Transplantation for Lymphoma in the Elderly: A Single Center Experience
Authors: Ghulam Rehman Mohyuddin, Shaun DeJarnette, Clint Divine, Tara L Lin, Leyla Shune, Sunil Abhyankar, Omar S. Aljitawi, Siddhartha Ganguly, Joseph McGuirk, Anurag K. Singh
Journal: Blood (2015)
Splenic metabolic activity as biomarker in cervical cancer
Authors: E.A. De Jaeghere, F. Laloo, L. Lippens, K. De Man, M. Van Bockstal, K. Van de Vijver, P. Tummers, A. Makar, P. De Visschere, O. De Wever, F. Amant, H. Denys, K. Vandecasteele
Journal: Annals of Oncology (2019)
Role of follow-up (FU) FDG-PET/CT (FU-FDG-PET/CT) in patients with locoregionally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) treated with chemotherapy and radiotherapy (RT), either concurrent (CRT) or sequential (ST)
Authors: B. Van Den Heuvel, C. Van Laer, P.M.C. Specenier
Journal: Annals of Oncology (2019)
FOLFOXIRI versus FOLFIRINOX in first-line chemotherapy in patients with advanced pancreatic cancer: A propensity score analysis
Authors: A. Vienot, H. Chevalier, C. Bolognini, E. Gherga, A. Meurisse, D. Vernerey, C. Borg, A. Turpin
Journal: Annals of Oncology (2019)
Bioactivation of napabucasin triggers reactive oxygen species–mediated cancer cell death
Authors: F.E.M. Froeling, I.I.C. Chio, M.A. Yao, M. Lucito, P. Alagesan, J. Li, A.-Y. Chang, Y. Park, H.A. Rogoff, D.A. Tuveson, J.D. Watson
Journal: Annals of Oncology (2019)
Abstract 15482: Complete Heart Block Following Catheter Ablation of a Posterolateral Accessory Pathway
Authors: Franz Schweis, Gordon Ho, David Krummen, Ulrika Birgersdotter-Green, Gregory Feld
Journal: Circulation (2018)

Introduction: Complete heart block (CHB) is a rare, but well-known complication of catheter ablation procedures involving areas in proximity to the atrioventricular (AV) node. We present a unique c...
Expression of estrogen receptor and programmed cell death-ligand 1 can be complementary prognostic factors in HPV-positive oropharyngeal squamous cell carcinoma
Authors: S. Kwon, E.S. Kim, S.-H. Ahn, W.-J. Jeong, Y.H. Jung, J.H. Paik, H. Kim
Journal: Annals of Oncology (2019)
Abstract 5145: Predictors of Coronary Heart Disease Events among Asymptomatic Individuals with Low LDL: The Multi-Ethnic Study of Atherosclerosis
Authors: Ron Blankstein, Matthew Budoff, Leslee J Shaw, David C Goff, Joseph F Polack, Joao Lima, Roger S Blumenthal, Khurram Nasir
Journal: Circulation (2008)

Even among individuals with low LDL, some will still experience coronary heart disease events (CHD-E) and may benefit from more aggressive therapies. Our aim was to identify risk factors for CHD-E ...
The validity of evaluations for chemotherapy-induced peripheral neuropathy (CIPN)
Authors: T. Yamada, Y. Yoshida, A. Satoh, N. Aisu, T. Matsuoka, T. Koganemaru, R. Kajitani, T. Munechika, Y. Matsumoto, H. Nagano, A. Komono, R. Sakamoto, M. Morimoto, H. Arima, S. Hasegawa
Journal: Annals of Oncology (2019)
Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in advanced renal cell carcinoma (RCC)
Authors: A-K A Lalani, Z. Bakouny, S. Farah, W. Xie, R. Flippot, J.A. Steinharter, P.V. Nuzzo, J. Fleischer, S.K. Pal, N. Rathi, A.R. Hansen, F. Donskov, S. Dudani, T. Yuasa, U. Vaishampayan, M. Subasri, J.C. Wells, N.S. Basappa, D.Y.C. Heng, T.K. Choueiri
Journal: Annals of Oncology (2019)
Treatment-free survival, with and without toxicity, as a novel outcome applied to immuno-oncology agents in advanced renal cell carcinoma
Authors: M.M. Regan, M.B. Atkins, T. Powles, L. Werner, C. Mantia, S. Yang, J.L. Johansen, S. Rao, K.M. Gooden, D.F. McDermott
Journal: Annals of Oncology (2019)
Association of Antidepressant Use With Adverse Health Outcomes
Authors: Elena Dragioti, Marco Solmi, Angela Favaro, Paolo Fusar-Poli, Paola Dazzan, Trevor Thompson, Brendon Stubbs, Joseph Firth, Michele Fornaro, Dimitrios Tsartsalis, Andre F. Carvalho, Eduard Vieta, Philip McGuire, Allan H. Young, Jae Il Shin, Christoph U. Correll, Evangelos Evangelou
Journal: JAMA Psychiatry (2019)

Antidepressant use is increasing worldwide. Yet, contrasting evidence on the safety of antidepressants is available from meta-analyses, and the credibility of these findings has not been quantified.To grade the evidence from published meta-analyses of observational studies that assessed the association between antidepressant use or exposure and adverse health outcomes.PubMed, Scopus, and PsycINFO were searched from database inception to April 5, 2019.Only meta-analyses of observational studies with a cohort or case-control study design were eligible. Two independent reviewers recorded the data and assessed the methodological quality of the included meta-analyses. Evidence of association was ranked according to established criteria as follows: convincing, highly suggestive, suggestive, weak, or not significant.Forty-five meta-analyses (17.9%) from 4471 studies identified and 252 full-text articles scrutinized were selected that described 120 associations, including data from 1012 individual effect size estimates. Seventy-four (61.7%) of the 120 associations were nominally statistically significant at P ≤ .05 using random-effects models. Fifty-two associations (43.4%) had large heterogeneity (I2 > 50%), whereas small-study effects were found for 17 associations (14.2%) and excess significance bias was found for 9 associations (7.5%). Convincing evidence emerged from both main and sensitivity analyses for the association between antidepressant use and risk of suicide attempt or completion among children and adolescents, autism spectrum disorders with antidepressant exposure before and during pregnancy, preterm birth, and low Apgar scores. None of these associations remained supported by convincing evidence after sensitivity analysis, which adjusted for confounding by indication.This study's findings suggest that most putative adverse health outcomes associated with antidepressant use may not be supported by convincing evidence, and confounding by indication may alter the few associations with convincing evidence. Antidepressant use appears to be safe for the treatment of psychiatric disorders, but more studies matching for underlying disease are needed to clarify the degree of confounding by indication and other biases. No absolute contraindication to antidepressants emerged from this umbrella review.
RARE-54. FIRST CASE OF PLEOMORPHIC XANTHOASTROCYTOMA OF THE PINEAL REGION IN A PATIENT WITH NEUROFIBROMATOSIS TYPE I
Authors: Mansour Mathkour, Juanita Garces, Tyler Scullen, Lauren Boehm, Joshua Hanna, Olawale A.R. Sulaiman, Cuong J. Bui
Journal: Neuro-Oncology (2016)

Pleomorphic Xanthoastrocytoma (PXA) describes a relatively rare and often focal glioma most commonly affecting children and young adults. Lesions are preferentially supratentorial and superficially located with a close association and occasional involvement of the leptomeninges, although infratentorial masses have been described. The World Health Organization (WHO) categorizes such tumors as Grade II, and surgical excision carries a favorable prognosis. Reportedly, PXA may be associated with Neurofibromatosis Type I (NF1), although such tumors are not a hallmark of the classic phenotype. In this report we describe a novel case of a pineal region PXA in a patient with a history of NF1. A 17-year-old male with a history of NF1 presented with complaints of bifrontal headache. Imaging of the head was ordered. Magnetic resonance imaging (MRI) was significant for a heterogeneous tectal mass suspicious for glioma extending to the level of the 4th ventricle with cerebral aqueduct displacement but no obstructive hydrocephalus. The patient underwent suboccipital craniotomy for an infratentorial supracerebellar approach to the pineal region and resection of tumor. Histopathology confirmed a low-grade variable neoplasm consistent with PXA. Post-operative imaging demonstrated gross total resection. There is no evidence of residual or recurrence at 3months follow-up. To the best of our knowledge, there are 8 prior reported cases of pineal region PXA with such lesions rarely occurring in individuals with NF1. These masses present similarly to dysplastic tumor types, and should be considered as a rare etiology of NF1 associated tectal masses.
Tumour-infiltrating lymphocytes and BRCA-like status in stage III breast cancer patients treated with intensified carboplatin-based chemotherapy
Authors: L. De Boo, A. Cimino-Mathews, Y. Lubeck, A. Daletzakis, M. Opdam, J. Sanders, E. Hooijberg, A.G.J. van Rossum, Z. Loncova, D. Rieder, Z. Trajanoski, M. Vollebergh, M. Sobral-Leite, K. Van de Vijver, A. Broeks, R. van der Wiel, H. van Tinteren, S.C. Linn, H. Horlings, M. Kok
Journal: Annals of Oncology (2019)
Safety, efficacy, and immune effects of intratumoral tilsotolimod in patients with refractory solid tumours: Updated results from ILLUMINATE-101
Authors: H. Babiker, E. Borazanci, V. Subbiah, O. Maguire, S. Rahimian, H. Minderman, C. Haymaker, C. Bernatchez, G. Bindra, I. Iverson, S. Chunduru, P. Anderson, I. Puzanov, A. Diab
Journal: Annals of Oncology (2019)
Efficacy and toxicity of weekly carboplatin and paclitaxel as induction or palliative treatment in advanced esophageal cancer patients
Authors: F.M. de Man, R.A.G. Van Eerden, E. Oomen-de Hoop, J.N. Veraart, N. van Doorn, L. van Doorn, A. van der Gaast, R.H.J. Mathijssen
Journal: Annals of Oncology (2019)
A phase I, open-label study of GSK1795091 administered in combination with immunotherapies in participants with advanced solid tumours (NCT03447314)
Authors: A.R. Hansen, J. Strauss, J. Chaves, S.A. Piha-Paul, H. Park, E. Garralda, C.J. Matheny, J. Carver, A. Moore, B.A. Hug
Journal: Annals of Oncology (2019)
Soft tissue sarcomas express a distinct mRNA immune profile
Authors: V. Grünwald, F. Laenger, A. Kunitz, M. Schuler, P. Schoeffski, H.-G. Kopp, S. Bauer, B. Kasper, L. Lindner, J.M. Chemnitz, M. Crysandt, A. Stein, B. Steffen, M. Kneba, G. Egerer, S. Zimmermann, P. Ivanyi, A. Karch
Journal: Annals of Oncology (2019)
Correlation Of Longitudinal Blood Counts With Thromboembolic Complications In WHO 2008 Defined Prefibrotic Primary Myelofibrosis
Authors: Veronika Buxhofer-Ausch, Martin Schalling, Sophie Frantal, Jürgen Thiele, Leonhard Muellauer, Hans-Michael Kvasnicka, Bettina Gisslinger, Heinz Gisslinger
Journal: Blood (2013)
Acute Care Utilization Is More Common in Patients with Sickle Cell Disease Who Have Chronic Complications and Chronic Pain: A Preliminary Report from the Escaped Trial
Authors: Sophie Lanzkron, Carlton Haywood, Jane A Little, Joshua Field, Joseph Ryan Shows, Jodi Segal, Mustapha Saheed, Derek Robertson, Marc V Proudford, Adrienne Kincaid, Lorri Burgess, Charles Green, Hang Wang, Rebecca Seufert, Jasmine Brooks, Brandi Griffin, Allie Piehet, Steven Frymark, Ravi Varadhan
Journal: Blood (2016)
A pilot trial to investigate the impact of a personalised self-management lifestyle programme using mobile technology on the health and wellbeing of cancer survivors
Authors: M.G. Kelly, J. Richmond, N. Singaroyan, T. Kerr, A. O’Donnell, E. Masterson, C. Haughey, O. Harney, J. Walsh, J. Groarke
Journal: Annals of Oncology (2019)
Abstract P008: Ultra-Sensitive Troponin I Strongly Predicts Incident Coronary Heart Disease in the General Population Independently of Traditional Risk Factors. Results From the MONICA/KORA Augsburg Case-Cohort Study
Authors: WolfgangKoenig, AstridZierer, MahirKarakas, ChristaMeisinger, AnnettePeters, JohnTodd, ChristianHerder, BarbaraThorand
Journal: Circulation (2014)

Background: High-sensitive (hs) troponin T and I assays as well as ultrasensitive (us) troponin I enable measurement of troponins in 65% to 98% of the general population. We prospectively investigated whether increased concentrations of us-troponin I are associated with an increased risk of coronary heart disease (CHD) after controlling for traditional risk factors. Methods: We conducted a population-based case cohort study in middle-aged healthy men and women within the MONICA/KORA Augsburg studies. Serum levels of us-troponin I (Single Molecule Counting technology, Singulex) were available in 2,745 men and women including 803 incident CHD cases. Geometric mean us-troponin I was 1.56 ng/L. Mean (SD) follow-up was 16.0 (5.8) years. Results: Baseline concentrations of us-troponin I were higher in cases compared to non-cases (geometric mean 2.56 vs. 1.49 ng/L, p<0.0001) and in men compared to women (geometric mean 1.93 vs. 1.27 ng/L, p<0.0001). After adjustment for variables of the Framingham Risk Score, th...
Immune-related gene expression signatures (irGES) in patients (pts) with ovarian clear cell carcinomas (OCCC): A multicenter analysis
Authors: V. Heong, T.Z. Tan, J. Ye, M. Miwa, D. Lim, C.S. Herrington, Y. Iida, A. Okamoto, J. Low, J. Ng, S.E. Lim, Y.W. Lim, C. Gourley, K. Hasegawa, D.S. Tan, R. Huang
Journal: Annals of Oncology (2019)
Development of a SOMAmer (slow off-rate modified aptamer)-based assay to detect NSCLC.
Authors: Noh Jin Park, Dana Root, Xiuqiang Wang, Angelica Diaz, Taraneh Esmailpour, Charlies e Birse, Robert Lagier, Weimin Sun, Robert J. Morrone, Frederic Waldman, Charles m Strom
Journal: Journal of Clinical Oncology (2013)

7601 Background: Support for low-dose helical computed tomography (CT) screening for lung cancer in a high risk population has emerged from the National Lung Screening Trial (NLST). However, the low specificity of CT raises concerns regarding the cost and potential morbidity associated with resection of benign nodules. Non-invasive lung cancer biomarkers may serve as a useful complement to imaging, providing a simple means to further clarify the diagnosis of suspicious pulmonary nodules. SOMAmer-based chip technology was previously used to identify a panel of serological biomarkers capable of accurately classifying NSCLC. Here we assess the analytical and clinical performance of an automated assay that uses SOMAmer reagents and qPCR to simultaneously quantify a subset of these markers (n=12). Methods: Biomarker levels were measured in sera from 43 subjects with stage I-III NSCLC and 63 long-term smoker controls. qPCR results were analyzed by relative (ΔΔC T ) quantitation, which uses calibrator serum and a set of normalizers. Linear mixed-effects models were fit to identify key sources of analytical variability (variance components), including plate-to-plate, within-sample, and between sample effects. Clinical performance for distinguishing NSCLC from control sera was established by a random forest predictive model. Results: Median within-sample %CV for the 12 markers was 6.7%. Variance components analyses suggest that, on average, 5.7% of the variance for a given biomarker was due to within-sample effects, 5.2% to plate-to-plate effects, and 86.2% to between-sample effects. A 10-marker random forest model exhibited an AUC [95% CI] of 0.915 [0.905, 0.924], classifying NSCLC from control sera with 79% sensitivity and 90% specificity. Conclusions: We have developed a highly reproducible automated assay designed for the clinical laboratory. Combining SOMAmer-based protein capture and qPCR-based quantification, the assay monitors the levels of 12 potential lung cancer markers. An algorithm-based model incorporating 10 of these markers showed good accuracy for distinguishing NSCLC from control sera. Further studies are warranted to evaluate the performance of the test in classifying pulmonary nodules.
Immune-related gene expression profiling after neoadjuvant chemotherapy (NACT) of ovarian high-grade serous carcinoma
Authors: L.M. Manso, I. Lodewijk, E Bernal Hertfelder, C. Suárez-Cabrera, J.L. Garcia, S. Wang, J.M. Paramio, M. Dueñas
Journal: Annals of Oncology (2019)
David Oliver: What’s behind the rise in dementia admissions?
Authors: David Oliver
Journal: BMJ (2019)

I recently woke to news headlines claiming that NHS hospitals were admitting “1000 dementia patients a day”—a rapid increase since 2013.1

The data came from NHS Digital. But the expert commentary, quoted in the Daily Mail and broadcast widely, came from the Alzheimer’s Society.2 It blamed social care cuts and claimed that dementia admissions generally harmed patients or left them unable to return home.

I care deeply about improving acute and community care in dementia, so I was pleased to see the topic get airtime. I don’t want to dampen the impact by nitpicking. But I do have some caveats.

Firstly, it isn’t news that many people in hospital beds have dementia or delirium. A decade ago, the NHS Confederation and the Alzheimer’s Society …
ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer
Authors: M. Ignatiadis, H.L. McArthur, A. Bailey, J. Martinez, E. de Azambuja, O. Metzger, C. Lai, M.A. Franzoi, T. Goulioti, F. Daly, A. Bouhlel, V. Balta, M. Maetens, G. Viale, B. André, C. DuFRane, D.A. Nguyen, R.D. Gelber, M. Piccart, E.P. Winer
Journal: Annals of Oncology (2019)
SAT0364 History of digital ulcers in patients with systemic sclerosis is associated with peripheral vasculopathy as assessed by videocapillaroscopy and 22-mhz power doppler ultrasonography
Authors: T Schioppo, A Orenti, P Boracchi, O De Lucia, A Murgo, PL Meroni, F Ingegnoli
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Vasculopathy is considered a primary pathogenic event in systemic sclerosis (SSc) and it substantially contributes to prominent features of the disease such as digital ulcers (DUs). History of DUs (HDUs) has been shown to correlate with disease severity, new cardiovascular events, new DUs and overall poor prognosis [1]. Microvascular abnormalities as assessed by nailfold videocapillaroscopy (NVC) and power Doppler ultrasound (PDUS) have been demonstrated to be predictive of new DUs occurrence [2,3]. <h3>Objectives</h3> To study the severity of microvascular involvement at the 3rd and 4th finger of the dominant hand in patients with SSc with or without HDUs as assessed by NVC and 22-MHz PDUS. <h3>Methods</h3> 100 SSc consecutive patients fulfilling the 2013 EULAR classification criteria were enrolled. PDUS was performed at the 3rd and 4th finger of the dominant hand after exclusion of ulnar artery occlusion (UAO). In case of UAO non-dominant hand was examined. Ultrasound investigation was performed with Esaote MyLab 70 XVG by means of linear array transducer (10–22 MHz). Power Doppler settings were standardized (Doppler frequency 14.3 MHz, Gain 55%, PRF 750 Hz). PDUS measurements included sagittal scan of nailbed and fingertip qualitatively graded from 1 (no signal) to 4 (marked hyperemia) [4], and resistivity index (RI) of ulnar and radial proper digital arteries. Capillary density (number/mm) was calculated by NVC with magnification 200X performed on two images of the same digits examined by PDUS. <h3>Results</h3> 100 SSc patients, 87 (87%) women, 86 (86%) limited cutaneous SSc, median age 62.2 years old, median disease duration 8 years were evaluated. 7 (7%) patients had UAO. 33 (33%) had HDUs among them 23 had experienced more than one DUs and 2 had active DUs at the moment of evaluation. Semiquantitative perfusion score of sagittal scan of nailbed and fingertip were not significantly associated with the presence of HDU. RI and capillary density were significantly different in the two groups as shown in the table below: <h3>Conclusions</h3> A significant lower RI of ulnar and radial proper digital arteries reported in patient with HDUs is novel. By contrast PDUS grading of nailfold and fingertip were not significantly different in patients with or without HDUs. The finding of a significant lower capillary number assed by NVC in patients with HDUs is consistent with previous results [2]. Adequately longitudinal studies exploring the predictive value of PDUS parameters are required to fully ascertain its role in SSc. <h3>References</h3> Mihai C et al. Ann Rheum Dis. 2016;75(4):681–6. Cutolo M et al. Arthritis Rheumatol. 2016;68(10):2527–39. Lescoat A et al. Arthritis Care Res. 2016;Epub ahead of print. Newman JS et al. Radiology. 1996,198:582–584. <h3>Disclosure of Interest</h3> None declared
KEYNOTE-495/KeyImPaCT: A randomized, biomarker-directed, phase II trial of pembrolizumab-based therapy for non–small cell lung cancer (NSCLC)
Authors: M. Gutierrez, W.-S. Lam, M.D. Hellmann, M.A. Gubens, C. Aggarwal, D.S.W. Tan, E. Felip, J.W.Y. Chiu, J.S. Lee, J C-H Yang, E.B. Garon, A. Basso, H. Ma, L. Fong, A. Snyder, J. Yuan, R.S. Herbst
Journal: Annals of Oncology (2019)
MFF Regulation of Mitochondrial Cell Death Is a Therapeutic Target in Cancer
Authors: Jae Ho Seo, Young Chan Chae, Andrew V. Kossenkov, Yu Geon Lee, Hsin-Yao Tang, Ekta Agarwal, Dmitry I. Gabrilovich, Lucia R. Languino, David W. Speicher, Prashanth K. Shastrula, Alessandra Maria Storaci, Stefano Ferrero, Gabriella Gaudioso, Manuela Caroli, Davide Tosi, Massimo Giroda, Valentina Vaira, Vito W. Rebecca, Meenhard Herlyn, Min Xiao, Dylan Fingerman, Alessandra Martorella, Emmanuel Skordalakes, Dario C. Altieri
Journal: Cancer Research (2019)

The regulators of mitochondrial cell death in cancer have remained elusive, hampering the development of new therapies. Here, we showed that protein isoforms of mitochondrial fission factor (MFF1 and MFF2), a molecule that controls mitochondrial size and shape, that is, mitochondrial dynamics, were overexpressed in patients with non-small cell lung cancer and formed homo- and heterodimeric complexes with the voltage-dependent anion channel-1 (VDAC1), a key regulator of mitochondrial outer membrane permeability. MFF inserted into the interior hole of the VDAC1 ring using Arg225, Arg236, and Gln241 as key contact sites. A cell-permeable MFF Ser223-Leu243 d-enantiomeric peptidomimetic disrupted the MFF-VDAC1 complex, acutely depolarized mitochondria, and triggered cell death in heterogeneous tumor types, including drug-resistant melanoma, but had no effect on normal cells. In preclinical models, treatment with the MFF peptidomimetic was well-tolerated and demonstrated anticancer activity in patient-derived xenografts, primary breast and lung adenocarcinoma 3D organoids, and glioblastoma neurospheres. These data identify the MFF-VDAC1 complex as a novel regulator of mitochondrial cell death and an actionable therapeutic target in cancer. SIGNIFICANCE: These findings describe mitochondrial fission regulation using a peptidomimetic agent that disturbs the MFF-VDAC complex and displays anticancer activity in multiple tumor models.See related commentary by Rao, p. 6074.